التفاصيل البيبلوغرافية
| العنوان: |
Pimasertib‐associated ophthalmological adverse events. |
| المؤلفون: |
Dijk, Elon H.C., Kruit, Wim H.J., Jager, Martine J., Luyten, Gregorius P.M., Vingerling, Johannes R., Boon, Camiel J.F. |
| المصدر: |
Acta Ophthalmologica (1755375X); Nov2018, Vol. 96 Issue 7, p712-718, 7p |
| مصطلحات موضوعية: |
RETINAL vein occlusion, MITOGEN-activated protein kinases, DIABETIC retinopathy, ADVERSE health care events, COLOR vision, OPTICAL coherence tomography, PROTEIN kinases |
| مستخلص: |
Purpose: To analyse ophthalmological adverse events associated with mitogen‐activated protein kinase kinase (MEK) inhibition with pimasertib treatment for metastatic cutaneous melanoma (CM). Methods: In this prospective observational, cohort‐based, cross‐sectional study, eight patients treated with the MEK inhibitor pimasertib received a complete ophthalmic examination. This included Early Treatment of Diabetic Retinopathy Study best‐corrected visual acuity, visual field testing, colour vision testing, slit‐lamp examination, applanation tonometry, indirect ophthalmoscopy, digital colour fundus photography and optical coherence tomography (OCT). In selected cases, fluorescein angiography was performed. Results: Serous subretinal fluid (SRF) developed in all patients, within a time frame of 9–27 days after the start of treatment. The fovea was involved in six of eight patients (75%). None of the patients with foveal SRF [excluding a patient who developed a bilateral retinal vein occlusion (RVO)] experienced visual symptoms. Subretinal fluid (SRF) decreased or resolved in all patients, despite continuation of study medication in six of eight patients (75%). Complaints in the CM patient (13%) consisted of experiencing a dark fleck in the inferior part of the visual field of the right eye 1 week after the start of treatment, due to an RVO. Subsequent intravitreal bevacizumab treatment resulted in functional and anatomical improvement. Conclusion: Patients with metastatic CM who are treated with the MEK inhibitor pimasertib are at high risk of development of ocular adverse events including serous retinopathy and possibly RVO, stressing the need of adequate ophthalmological follow‐up including OCT during administration of pimasertib, despite the fact that SRF generally does not lead to ophthalmological complaints. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Ophthalmologica (1755375X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder